DGDA revokes registration of 4 medicines
The Directorate General of Drug Administration (DGDA) has revoked the registrations of four medicinal drugs.
Those are – Rabeprazole Sodium Enteric Coated Pellets 8.5% w/w Ph grade 235.294mg (Contains Rabenprazole Sodium BP 20mg Capsule), Bromelain 50mg + Tripsyn 1mg Tablet, Antaxanthin INN 2mg and Antaxanthin INN 4mg.
DGDA's Drug Control Committee took the decision at its 253rd meeting on Monday, said a press release.
Keep updated, follow The Business Standard's Google news channel
Registration of four veterinary drugs was also cancelled during the meeting.
DGDA's meeting statement said due to a lack of necessary references as MUPS Rabeprazole Sodium Delayed release pellets 15% w/w (Mups) ph, Grade 133.133mg, MUPS tablet was cancelled at the 252nd meeting of the Drug Control Committee.
Ayub Hossain, a director and spokesperson of the DGDA, told The Business Standard, "Their registrations have been cancelled as some confusions arose about the safety of these medicines."
"The veterinary drugs can cause Antimicrobial Resistance in humans, that is why their licences were also cancelled," he added.
